Cargando…

A Review on the Efficacy and Safety of Oral Semaglutide

There are numerous treatment options currently available for patients with type 2 diabetes mellitus; however, a multitude of patients continue to have inadequately controlled glycemic levels with their current antihyperglycemic regimen. Furthermore, the American Diabetes Association guidelines incre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niman, Stephanie, Hardy, Jennifer, Goldfaden, Rebecca F., Reid, Jessica, Sheikh-Ali, Mae, Sutton, David, Choksi, Rushab
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206300/ https://www.ncbi.nlm.nih.gov/pubmed/33772451 http://dx.doi.org/10.1007/s40268-021-00341-8

Ejemplares similares

A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
por: Rana, Khyatiben, et al.
Publicado: (2019)

Association of chronic neutrophil activation with risk of mortality
por: Penn, Marc S., et al.
Publicado: (2023)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis
por: Tan, Hanna Clementine, et al.
Publicado: (2022)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
por: Meier, Juris J.
Publicado: (2021)

Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme
por: Aroda, Vanita R., et al.
Publicado: (2022)

Efficacy, safety, and patient satisfaction with oral semaglutide: first single-centre clinical experience
por: Janić, Miodrag, et al.
Publicado: (2023)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
por: Bækdal, Tine A., et al.
Publicado: (2018)

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
por: Granhall, Charlotte, et al.
Publicado: (2018)

Efficacy and safety of semaglutide in non-alcoholic fatty liver disease
por: Zhu, Kai, et al.
Publicado: (2023)

Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis
por: Zhong, Ping, et al.
Publicado: (2021)

Oral Semaglutide: Dosage in Special Situations
por: Kalra, Sanjay, et al.
Publicado: (2022)

The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis
por: Alhindi, Yousef, et al.
Publicado: (2022)

Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
por: Thethi, Tina K., et al.
Publicado: (2020)

A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction
por: Huston, Jessica, et al.
Publicado: (2023)

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
por: Buse, John B, et al.
Publicado: (2020)

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
por: Xie, Zeyu, et al.
Publicado: (2022)

Advances in GLP-1 treatment: focus on oral semaglutide
por: Eliaschewitz, Freddy G., et al.
Publicado: (2021)

Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
por: Gallwitz, Baptist, et al.
Publicado: (2021)

Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes
por: Mora, Pablo F, et al.
Publicado: (2020)

OR30-02 Efficacy and Safety Comparison Between U100 Regular Human Insulin and U100 Rapid Acting Insulin When Delivered by a 24 Hour Wearable Insulin Delivery Device in Type 2 Diabetes
por: Mora, Pablo, et al.
Publicado: (2020)

Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis
por: Shi, Fang-Hong, et al.
Publicado: (2018)

Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review
por: Ahmed, Nabeel R, et al.
Publicado: (2022)

Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study
por: Arai, Taeang, et al.
Publicado: (2022)

Abstract 138: Efficacy of oral semaglutide according to race: An exploratory subgroup analysis of the PIONEER trial program
por: Srivastava, Kunal, et al.
Publicado: (2022)

Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis
por: Smith, Inger, et al.
Publicado: (2022)

Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials
por: Yabe, Daisuke, et al.
Publicado: (2022)

Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials
por: Yamada, Yuichiro, et al.
Publicado: (2021)

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
por: Verma, Subodh, et al.
Publicado: (2022)

Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
por: Kane, Michael P, et al.
Publicado: (2020)

First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
por: Rajput, Rajesh, et al.
Publicado: (2022)

Oral Semaglutide: Balancing Promising Therapeutics with Adverse Effects and Access Barriers
por: Gunning, Karen
Publicado: (2020)

Semaglutide for the treatment of overweight and obesity: A review
por: Bergmann, Natasha Chidekel, et al.
Publicado: (2022)

Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs)
por: Anam, Mahvish, et al.
Publicado: (2022)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials
por: Zhang, Rui, et al.
Publicado: (2023)

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
por: Kaku, Kohei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nhtmoeqecnvtsplnqvse4k5kvq